98406-04-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Chloro-5-hydroxybenzoic acid methyl ester is used as a starting material for the synthesis of pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable component in the development of new drugs and therapeutic agents, contributing to advancements in healthcare and agriculture.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Chloro-5-hydroxybenzoic acid methyl ester is used as a building block for the preparation of various biologically active compounds. Its versatility and reactivity enable the creation of a wide range of molecules with potential applications in medicine, agriculture, and other industries.
Used in Flavor and Fragrance Industry:
3-Chloro-5-hydroxybenzoic acid methyl ester is used as a component in the manufacturing of flavors and fragrances. Its unique chemical properties contribute to the development of diverse scents and tastes, enhancing the sensory experience of various products.
Used in Dye Manufacturing:
This versatile compound is also used in the production of dyes, where its chemical properties contribute to the creation of a wide range of colors. Its applications in dye manufacturing extend to various industries, including textiles, plastics, and printing, where colorants are essential for product development and design.

Upstream product

• 96826-41-4 methyl 3-chloro-5-methoxybenzoate 
• 82477-67-6 3-chloro-5-methoxy-benzoic acid 
• 51-36-5 3,5-dichlorobenzoic acid 
• 2905-65-9 methyl 3-chlorobenzoate 
• 67-56-1 methanol 
• 53984-36-4 3-chloro-5-hydroxybenzoic acid 
• 408492-29-5 methyl 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 

Downstream Products

• 98406-05-4 methyl 3-chloro-5-methoxymethyloxybenzoate 
• 899808-12-9 C₁₄H₂₁ClO₃Si 
• 899808-14-1 C₁₅H₂₃ClO₃Si 
• 899808-13-0 C₁₃H₂₁ClO₂Si 
• 899808-15-2 3-chloro-5-hydroxybenzyl acetate 
• 53985-44-7 3-(benzyloxy)-5-chlorobenzoic acid 
• 879542-69-5 3-chloro-5-(2-methoxy-ethoxy)-benzoic acid methyl ester 
• 1042023-63-1 C₁₆H₁₅ClO₄ 
• 98406-10-1 1-<1-<2-<(3-chloro-5-hydroxybenzyl)oxy>phenyl>vinyl>-1H-imidazole hydrochloride 
• 98406-08-7 1-<1-<2-<(3-chloro-5-methoxymethyloxybenzyl)oxy>phenyl>vinyl>-1H-imidazole 
• 98406-06-5 3-chloro-5-methoxymethyloxybenzyl alcohol 

Relevant academic research and scientific papers

Sulfoximine-Assisted One-Pot Unsymmetrical Multiple Annulation of Arenes: A Combined Experimental and Computational Study

Discussed herein is an unprecedented Ru-catalyzed one-pot unsymmetrical C-H difunctionalization of arenes comprising intramolecular hydroarylation of olefins and intermolecular annulation of alkynes. This unprecedented 2-fold C-H functionalization is validated on the basis of experimental and density functional theory (DFT) study. The transformation readily occurs with the assistance of methylphenyl sulfoximine (MPS) directing group in the presence of Ru catalyst forming two C-C and one C-N bonds in a single operation. The overall process is atom economical and step-efficient and provides unusual dihydrofuran-fused isoquinolone heterocycles. Further annulation of NH and the proximal o-C-H-arene of isoquinolone with alkynes build highly conjugated novel polycyclic compounds. Overall, three independent annulations in arene motifs are visualized and thoughtfully executed; finally, 5 ring-fused structural entities are constructed forming three C-C and two C-N bonds.

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Practical one-pot C-H activation/borylation/oxidation: Preparation of 3-bromo-5-methylphenol on a multigram scale

A practical one-pot C-H activation/borylation/oxidation sequence for the generation of 3,5-disubstituted phenols is presented. Specifically, 3-bromo-5-methylphenol is prepared from 3-bromotoluene, without isolation of intermediates, on a multigram scale, and in high yield. The process proceeds under mild conditions and can be completed within one day. Georg Thieme Verlag Stuttgart - New York.

PROSTAGLANDIN PRODUGS AS HYPOTENSIVE AGENTS

Therapeutic compounds, methods, and compositions are disclosed herein for treating glaucoma and baldness in mammals. The specific compounds are described herein and are modified prostaglandin derivates.

Substituted Cyclopentanes Or Cyclopentanones As Therapeutic Agents

Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.

SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS

Therapeutic compounds, methods, and compositions are disclosed herein.

Process for the synthesis of phenols from arenes

A process to synthesize substituted phenols such as those of the general formula RR′R″Ar(OH) wherein R, R′, and R″ are each independently hydrogen or any group which does not interfere in the process for synthesizing the substituted phenol including, but not limited to, halo, alkyl, alkoxy, carboxylic ester, amine, amide; and Ar is any variety of aryl or hetroaryl by means of oxidation of substituted arylboronic esters is described. In particular, a metal-catalyzed C—H activation/borylation reaction is described, which when followed by direct oxidation in a single or separate reaction vessel affords phenols without the need for any intermediate manipulations. More particularly, a process wherein Ir-catalyzed borylation of arenes using pinacolborane (HBPin) followed by oxidation of the intermediate arylboronic ester by OXONE is described.